<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="165287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946153</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-J081-202</org_study_id>
    <nct_id>NCT00946153</nct_id>
  </id_info>
  <brief_title>Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and
      tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is
      administered continually once daily in patients with advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Escalation Component: To determine the MTD defined by dose-limiting toxicity (DLT) of E7080. Safety assessments based on adverse events, physical exams, and selected lab values.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion Component: Time to progression.</measure>
    <time_frame>From day of registration to the day when progressive disease is first confirmed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Component: To evaluate the anti-tumor effect of E7080 using Response Evaluation Criteria in Solid Tumors (RECIST).</measure>
    <time_frame>Every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion Component: Progression-free survival.</measure>
    <time_frame>From day of registration to the day when progressive disease is first confirmed or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion Component: Objective response rate.</measure>
    <time_frame>Every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion Component: Disease control rate.</measure>
    <time_frame>At 8 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion Component: Overall survival.</measure>
    <time_frame>From day of registration to the day of death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7080</intervention_name>
    <description>In the Dose-Escalation Component of the study, E7080 will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or clinically confirmed diagnosis of advanced HCC

          2. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS): 0-1

          3. Adequate laboratory values/organ function tests

        Exclusion criteria:

          1. Simultaneous or metachronous cancers

          2. Pericardial, ascites, or pleural effusion requiring drainage

          3. Brain metastasis/meningeal carcinomatosis presenting clinical symptoms or requiring
             treatment

          4. Malabsorption syndrome

          5. Artery-portal vein shunt or artery-vein shunt preventing proper diagnosis of tumor

          6. Use of drugs known to inhibit cytochrome P3A4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takuya Suzuki</last_name>
    <role>Study Director</role>
    <affiliation>Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Musashino-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 19, 2015</lastchanged_date>
  <firstreceived_date>July 23, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Hepatocellular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
